HC Wainwright Has Lowered Expectations for Vivos Therapeutics (NASDAQ:VVOS) Stock Price

Vivos Therapeutics (NASDAQ:VVOS) had its target price cut by research analysts at HC Wainwright from $7.00 to $2.50 in a report released on Friday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 156.65% from the stock’s current price.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vivos Therapeutics has an average rating of “Hold” and a consensus price target of $3.42.

Vivos Therapeutics Price Performance

VVOS opened at $0.97 on Friday. The company has a 50-day moving average of $1.35 and a 200-day moving average of $1.97. The company has a market capitalization of $13.14 million, a P/E ratio of -0.47 and a beta of 6.93. Vivos Therapeutics has a 1-year low of $0.96 and a 1-year high of $7.95. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.78 and a current ratio of 0.78.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Wednesday, April 15th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.08). Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%. The business had revenue of $3.82 million during the quarter, compared to analyst estimates of $7.10 million. During the same period last year, the firm posted ($2.22) earnings per share. Equities analysts expect that Vivos Therapeutics will post -1.79 EPS for the current fiscal year.

Insider Activity at Vivos Therapeutics

In other Vivos Therapeutics news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was acquired at an average cost of $1.34 per share, with a total value of $1,813,857.50. Following the acquisition, the insider owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. DRW Securities LLC boosted its stake in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the period. Acorn Wealth Advisors LLC acquired a new position in Vivos Therapeutics during the 4th quarter valued at about $30,000. Connective Capital Management LLC acquired a new position in Vivos Therapeutics during the 3rd quarter valued at about $620,000. B. Riley Wealth Advisors Inc. acquired a new position in Vivos Therapeutics during the 2nd quarter valued at about $220,000. Finally, XTX Topco Ltd acquired a new position in Vivos Therapeutics during the 2nd quarter valued at about $65,000. 26.35% of the stock is owned by institutional investors and hedge funds.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.